Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Poseida Therapeutics Q4 EPS $(0.27) Beats $(0.39) Estimate, Sales $25.00M Beat $6.65M Estimate

Author: Happy Mohamed | March 07, 2024 05:38pm
Poseida Therapeutics (NASDAQ:PSTX) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.39) by 30.77 percent. This is a 30.77 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $25.00 million which beat the analyst consensus estimate of $6.65 million by 275.86 percent. This is a 148.68 percent increase over sales of $10.05 million the same period last year.

Posted In: PSTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist